Form 4: 4D Molecular Therapeutics CLO Sells Shares

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and subsequently sold a portion of his common stock holdings.

Summary

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, engaged in transactions involving the company's common stock.
• On October 24, 2025, Bizily acquired 1,084 shares of common stock through the exercise of stock options at a price of $6.49 per share.
• On the same date, he disposed of 2,678 shares of common stock at a price of $12.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, Bizily directly beneficially owns 3,594 shares of common stock.
• Bizily also holds 9,295 derivative securities in the form of stock options (right to buy) with an exercise price of $6.49, after exercising 1,084 options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (exercise and sale) under a 10b5-1 plan, which typically does not indicate a significant positive or negative signal for the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled, non-opportunistic sale.
• The exercise of stock options at $6.49 and subsequent sale of shares at $12.00 demonstrates the realization of value from equity compensation for the Chief Legal Officer.

Negatives

• The Chief Legal Officer reduced his direct beneficial ownership of common stock by 1,594 shares (2,678 sold 1,084 acquired) through these transactions.

Future Outlook

This filing, a Form 4, reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details an insider transaction by a Chief Legal Officer, which is a routine disclosure required by the SEC. It does not provide information related to broader industry trends or competitive landscape, but rather reflects an individual's equity compensation management.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Legal Officer, even if pre-planned, slightly reduces insider ownership, which some investors might view with minor concern, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of a portion of common stock. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not considered highly indicative of the company's future performance or a strong signal for investment action. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

4D Molecular Therapeutics, FDMT, Scott Bizily, Insider Transaction, Form 4, Stock Option Exercise, Common Stock Sale, 10b5-1 Plan, Chief Legal Officer